Long Non-Coding RNAs as New Master Regulators of Resistance to Systemic Treatments in Breast Cancer.

ABSTRACT: Predicting response to systemic treatments in breast cancer (BC) patients is an urgent, yet still unattained health aim. Easily detectable molecules such as long non-coding RNAs (lncRNAs) are the ideal biomarkers when they act as master regulators of many resistance mechanisms, or of mechanisms that are common to more than one treatment. These kinds of markers are pivotal in quasi-personalized treatment selection, and consequently, in improvement of outcome prediction. In order to provide a better approach to understanding development of disease and resistance to treatments, we reviewed current literature searching for lncRNA-associated systemic BC treatments including endocrine therapies, aromatase inhibitors, selective estrogen receptor modulators (SERMs), trastuzumab, paclitaxel, doceta

SUBMITTER: Campos-Parra AD 

PROVIDER: S-EPMC6164317 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature